Research analysts who have asked questions during CYBN earnings calls.
AP
Andrew Partheniou
Stifel
2 questions for CYBN
Also covers: CRLBF, GTBIF, TCNNF
CD
Charles Duncan
Cantor Fitzgerald & Co.
2 questions for CYBN
Also covers: ACAD, ALKS, ATAI +12 more
FB
François Brisebois
Oppenheimer & Co. Inc.
2 questions for CYBN
Also covers: ACHV, AQST, AVDL +11 more
SK
Sumant Kulkarni
Canaccord Genuity
2 questions for CYBN
Also covers: ACAD, ATAI, BTAI +7 more
EP
Elemer Piros
Rodman & Renshaw
1 question for CYBN
Also covers: BRTX, CMPS, CRBP +2 more
JS
Jason Shieh
H.C. Wainright
1 question for CYBN
Michael Okunewitch
Maxim Group
1 question for CYBN
Also covers: BLFS, BLTE, BNGO +11 more
Patrick Trucchio
H.C. Wainwright & Co.
1 question for CYBN
Also covers: ALT, ARWR, ATAI +13 more
SM
Sepehr Manochehry
Eight Capital
1 question for CYBN
Recent press releases and 8-K filings for CYBN.
Cybin Inc. Rebrands as Helus Pharma and Commences Trading on Nasdaq
CYBN
New Projects/Investments
Delisting/Listing Issues
- Cybin Inc. has rebranded and will now operate under the business name Helus Pharma.
- The company has transferred its U.S. stock exchange listing from the NYSE American (previous ticker: CYBN) to the Nasdaq Global Market, trading under the new ticker symbol HELP.
- Helus Pharma is progressing its lead drug candidates, HLP003 (Phase 3 for major depressive disorder with Breakthrough Therapy Designation) and HLP004 (Phase 2 for generalized anxiety disorder), with HLP004 topline data expected in Q1 2026.
Jan 5, 2026, 9:51 PM
Cybin Inc. Launches US$100 Million At-The-Market Equity Program
CYBN
New Projects/Investments
- Cybin Inc. announced the launch of an at-the-market (ATM) equity program on December 30, 2025.
- The ATM Program allows the company to issue and sell up to US$100,000,000 of common shares from treasury.
- Shares will be sold through Cantor Fitzgerald and Co. and Cantor Fitzgerald Canada Corporation at prevailing market prices.
- The net proceeds from the sales are intended for growth opportunities and working capital initiatives.
- The program is effective until the earlier of the issuance of all shares or October 17, 2027.
Dec 31, 2025, 8:13 PM
Cybin Initiates At-The-Market Equity Program
CYBN
- Cybin Inc. has launched an at-the-market equity program (ATM Program) allowing it to issue and sell up to US$100,000,000 of common shares.
- The net proceeds from sales under the ATM Program are intended for growth opportunities and working capital initiatives.
- The ATM Program will be effective until the earlier of the issuance and sale of all shares or October 17, 2027.
- As of December 30, 2025, there are 49,894,131 common shares issued and outstanding.
Dec 30, 2025, 9:21 PM
Cybin Initiates At-The-Market Equity Program
CYBN
New Projects/Investments
- Cybin Inc. has launched an at-the-market (ATM) equity program to issue and sell up to US$100,000,000 of common shares.
- The shares will be sold from treasury to the public through Cantor Fitzgerald and Co. and Cantor Fitzgerald Canada Corporation.
- The net proceeds from the program are intended for growth opportunities and working capital initiatives.
- The ATM Program is effective until the earlier of the issuance and sale of all shares or October 17, 2027.
Dec 30, 2025, 8:33 PM
Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq
CYBN
Delisting/Listing Issues
- Cybin Inc. will transfer its U.S. stock exchange listing from the NYSE American LLC to the Nasdaq Global Market.
- The company's common shares are expected to cease trading on the NYSE American at market close on January 4, 2026, and commence trading on Nasdaq at market open on January 5, 2026.
- Concurrent with the Nasdaq trading commencement, the company will begin doing business as Helus Pharma (pronounced "Heal Us") and its ticker symbol will change from "CYBN" to "HELP" on January 5, 2026, for both Nasdaq and Cboe Canada.
Dec 18, 2025, 10:07 PM
Cybin Announces Closing of $175 Million Registered Direct Offering
CYBN
New Projects/Investments
- Cybin Inc. announced a registered direct offering on October 28, 2025, and subsequently closed it on October 31, 2025.
- The offering generated aggregate gross proceeds of US$175,009,911.45.
- The offering included 22,277,750 common shares and 4,605,500 pre-funded Common Share purchase warrants, each priced at US$6.51. Each share and pre-funded warrant was accompanied by 0.35 of one Common Share purchase warrant, exercisable at US$8.14 per share.
- The net proceeds are intended to repay outstanding unsecured convertible debentures held by High Trail Special Situations LLC, progress the Company's CYB003, CYB004, and CYB005 programs, and for working capital and general corporate purposes.
Nov 26, 2025, 4:46 PM
Cybin Reports Q2 2026 Financial Results and Completes $175 Million Offering
CYBN
Earnings
New Projects/Investments
- Cybin reported a net loss of $33,722 thousand and a basic loss per share of $1.39 for the second quarter ended September 30, 2025.
- As of September 30, 2025, the company's cash and cash equivalents were $83,752 thousand.
- On October 31, 2025, Cybin completed a registered direct offering, raising approximately $175,010 thousand in gross proceeds.
- After giving effect to the net proceeds from the offering, the company's pro-forma cash position as of September 30, 2025, would be US$248 million.
- The company is on track to report topline data from its Phase 2 study of CYB004 for Generalized Anxiety Disorder in Q1 2026 and continues to advance Phase 3 studies of CYB003 for major depressive disorder.
Nov 13, 2025, 12:24 PM
Cybin Announces Closing of $175 Million Registered Direct Offering
CYBN
New Projects/Investments
Debt Issuance
- Cybin Inc. closed a registered direct offering on October 31, 2025, generating aggregate gross proceeds of US$175,009,911.45.
- The offering included 22,277,750 common shares and 4,605,500 pre-funded Common Share purchase warrants at a price of US$6.51 per Common Share or Pre-Funded Warrant.
- The net proceeds are intended for repaying outstanding unsecured convertible debentures held by High Trail Special Situations LLC, advancing the CYB003, CYB004, and CYB005 programs, and for working capital and general corporate purposes.
Oct 31, 2025, 9:13 PM
Cybin Inc. Enters Securities Purchase Agreement and Engages Placement Agents for Offering
CYBN
- Cybin Inc. entered into a Securities Purchase Agreement on October 28, 2025, for an offering of its securities.
- The company engaged Jefferies LLC, TD Securities (USA) LLC, Cantor Fitzgerald & Co. as joint lead placement agents and Bloom Burton Securities Inc. as a placement agent on October 27, 2025, for a proposed placement of common shares, share warrants, and pre-funded warrants.
- Each common share or pre-funded warrant is being sold together with 0.35 of one share warrant.
- As of the document date, 27,616,381 Common Shares are issued and outstanding, along with 4,187,610 options and 106,255,498 warrants to purchase 2,796,197 Common Shares.
- The company's common shares are listed for trading on NYSE American and Cboe Canada under the symbol "CYBN".
Oct 29, 2025, 10:00 AM
Cybin Inc. Announces $175 Million Registered Direct Offering
CYBN
Convertible Preferred Issuance
New Projects/Investments
- Cybin Inc. announced a registered direct offering to raise US$175,009,911.45 in aggregate gross proceeds.
- The offering includes 22,277,750 common shares or pre-funded common share purchase warrants at a price of US$6.51 per Common Share or Pre-Funded Warrant. Each is accompanied by 0.35 of one common share purchase warrant exercisable at US$8.14 per Common Share.
- The company intends to use the net proceeds to repay outstanding unsecured convertible debentures held by High Trail Special Situations LLC, progress its CYB003, CYB004, and CYB005 programs, and for general corporate purposes.
- The financing includes participation from new and existing investors, such as Venrock Healthcare Capital Partners, OrbiMed, and Point72.
Oct 28, 2025, 12:52 PM
Quarterly earnings call transcripts for CYBN.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more